Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Next Previous
X
Search
Trial Profile

A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacritin (Primary)
  • Indications Dry eyes
  • Focus First in man; Therapeutic Use
  • Sponsors TearSolutions

    • Most Recent Events

    • 01 Jul 2023 Results assessing the safety, tolerability, dosing, and efficacy of the active 19 amino acid fragment of lacritin (Lacripep), a broad regulator of ocular surface homeostasis, in the treatment of ocular surface disease associated with primary Sjogren syndrome, published in the Cornea.
    • 16 Jan 2020 Status changed from active, no longer recruiting to completed.
    • 13 Nov 2019 Planned End Date changed from 31 Oct 2019 to 26 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top